Literature DB >> 29431149

Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal C. trachomatis and N. gonorrhoeae infections-a cross-sectional, single-center study.

Julian Storim1,2, Jens Verheyen3,4, Eva Wolff1,5, Jeremias Wohlschlaeger6,7, Evelyn Heintschel von Heinegg8, Dirk Schadendorf1, Stefan Esser1.   

Abstract

OBJECTIVES: Rectal infections with Chlamydia trachomatis and/or Neisseria gonorrhoeae (CT/NG) are common in men who have sex with men (MSM) and are linked to HIV transmission. However, rectal CT/NG infections are often asymptomatic and it is not known how they contribute to HIV transmission. We assessed clinical and cytological signs of inflammation as well as rectal HIV-RNA in HIV-infected MSM with and without CT/NG infection.
METHODS: 112 HIV-positive MSM with or without rectal symptoms and with or without antiretroviral therapy who underwent high-resolution anoscopy (HRA) at the proctological outpatient centre of the University Hospital Essen, Germany, between November 2013 and February 2014 were included in this cross-sectional study. During the examination, rectal swabs for the assessment of CT/NG, HIV-RNA and inflammatory cells (granulocytes, lymphocytes, histiocytes) were collected. 110 patients were assessed according to the study protocol, and no imputation of missing data was performed.
RESULTS: Rectal infections with CT or NG were detected in 17 participants, and 4 participants were coinfected. Only symptomatic CT/NG infections (8/17) showed signs of inflammation in HRA. Symptomatic CT/NG infections were also associated with the detection of lymphocytes and histiocytes in rectal cytology (both P<0.001). In contrast, asymptomatic CT/NG infections neither resulted in clinical nor cytological signs of inflammation. Rectal HIV-RNA was undetectable in all participants with rectal CT/NG infections who received combined antiretroviral therapy (ART) when plasma HIV-RNA was below the limit of detection (n=13). Besides rectal CT/NG infections, syphilis (n=4) and HPV-associated lesions (n=37) were frequently detected, and proctological symptoms were associated with simultaneous infection with ≥2 STDs.
CONCLUSIONS: Only symptomatic but not asymptomatic rectal infections with CT and/or NG were associated with clinical and cytological signs of inflammation. Rectal HIV shedding was not promoted by CT/NG infections in patients receiving ART with suppressed plasma HIV-RNA. TRIAL REGISTRATION NUMBER: UTN: U1111-1150-4804. German Clinical Trials Register (DRKS): DRKS00005468. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Hiv; chlamydia trachomatis; inflammation; neisseria gonorrhoea

Mesh:

Substances:

Year:  2018        PMID: 29431149     DOI: 10.1136/sextrans-2017-053409

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  2 in total

1.  High prevalence of sexually transmitted infections and risk factors among HIV-positive individuals in Yunnan, China.

Authors:  Wei Tu; Yu-Ye Li; Yi-Qun Kuang; Rong-Hui Xie; Xing-Qi Dong; Dan Zhang; Yan-Ling Ma; Wan-Yue Zhang; Lin Lu
Journal:  Eur J Med Res       Date:  2022-01-13       Impact factor: 2.175

2.  Sexually transmitted infections and HIV RNA levels in blood and anogenital compartments among Thai men who have sex with men before and after antiretroviral therapy: implication for Treatment as Prevention programme.

Authors:  Nittaya Phanuphak; Supanit Pattanachaiwit; Tippawan Pankam; Nipat Teeratakulpisarn; Parinya Chamnan; Panita Pathipvanich; Suchart Thongpaen; Siriporn Nonenoy; Jureeporn Jantarapakde; Supabhorn Pengnonyang; Deondara Trachunthong; Thanthip Sungsing; Kittiyaporn Parasate; Sriprai Seeneewong Na Ayutthaya; Ketmookda Trairat; Kanitta Pussadee; Cheewanan Lertpiriyasuwat; Praphan Phanuphak
Journal:  J Int AIDS Soc       Date:  2018-09       Impact factor: 5.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.